Metastatic colorectal carcinoma patients: The Glasgow Prognostic Score (GPS) at the era of anti-EGFR therapies

被引：0
|
作者：
Dreanic, J. [1 ]
Maillet, M. [1 ]
Dhooge, M. [1 ]
Cessot, A. [2 ]
Mir, O. [2 ]
Brezault, C. [1 ]
Goldwasser, F. [2 ]
Chaussade, S. [1 ]
Coriat, R. [1 ]
机构：
[1] Paris Descartes Univ, Cochin Teaching Hosp, AP HP, Dept Gastroenterol, Paris, France
[2] Paris Descartes Univ, Cochin Teaching Hosp, AP HP, Dept Oncol, Paris, France
来源：
EUROPEAN JOURNAL OF CANCER | 2013年 / 49卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2290
引用
收藏
页码：S525 / S525
页数：1
相关论文
共 50 条
  • [41] The application of the Glasgow prognostic score to predict the survival in patients with metastatic pancreatic carcinoma
    Mohammed, Amrallah A.
    Al-Zahrani, Omar
    Elsayed, Fifi Mostafa
    INDIAN JOURNAL OF PALLIATIVE CARE, 2022, 28 (04) : 406 - 412
  • [42] Potential biomarkers for anti-EGFR therapy in metastatic colorectal cancer
    Yang, Jiao
    Li, Shuting
    Wang, Biyuan
    Wu, Yinying
    Chen, Zheling
    Lv, Meng
    Lin, Yayun
    Yang, Jin
    TUMOR BIOLOGY, 2016, 37 (09) : 11645 - 11655
  • [43] Current concepts of anti-EGFR targeting in metastatic colorectal cancer
    Doleschal, Bernhard
    Petzer, Andreas
    Rumpold, Holger
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [44] Anti-EGFR Therapy to Treat Metastatic Colorectal Cancer: Not for All
    Martins, Marta
    Mansinho, Andre
    Cruz-Duarte, Raquel
    Martins, Soraia Lobo
    Costa, Luis
    TARGETED THERAPY OF COLORECTAL CANCER SUBTYPES, 2018, 1110 : 113 - 131
  • [45] Economic analysis of biomarker-based anti-EGFR therapies in metastatic colorectal cancer in the Austrian context
    Niedersüß-Beke D.
    Simon J.
    Schiffinger M.
    Mader R.M.
    memo - Magazine of European Medical Oncology, 2018, 11 (4) : 322 - 329
  • [46] The colorectal carcinoma - treatment research and treatment reality in oncology practices (Anti-VEGE or Anti-EGFR therapies)
    Tessen, H. -W
    Rubanov, O. Z.
    Grundeis, M.
    Teich, M.
    Elsel, W.
    Schlichting, A.
    Valdix, A.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 95 - 96
  • [47] The colorectal carcinoma - treatment research and treatment reality in oncology practices (Anti-VEGF or Anti-EGFR therapies)
    Tessen, H. W.
    Rubanov, O.
    Schlichting, A.
    Valdix, A.
    ANNALS OF ONCOLOGY, 2016, 27
  • [48] Heterogeneity of Acquired Resistance to Anti-EGFR Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer
    Pietrantonio, Filippo
    Vernieri, Claudio
    Siravegna, Giulia
    Mennitto, Alessia
    Berenato, Rosa
    Perrone, Federica
    Gloghini, Annunziata
    Tamborini, Elena
    Lonardi, Sara
    Morano, Federica
    Picciani, Benedetta
    Busico, Adele
    Volpi, Chiara Costanza
    Martinetti, Antonia
    Battaglin, Francesca
    Bossi, Ilaria
    Pellegrinelli, Alessio
    Milione, Massimo
    Cremolini, Chiara
    Di Bartolomeo, Maria
    Bardelli, Alberto
    de Braud, Filippo
    CLINICAL CANCER RESEARCH, 2017, 23 (10) : 2414 - 2422
  • [49] Nanofluidic Digital PCR and Extended Genotyping of RAS and BRAF for Improved Selection of Metastatic Colorectal Cancer Patients for Anti-EGFR Therapies
    Azuara, Daniel
    Santos, Cristina
    Lopez-Doriga, Adriana
    Grasselli, Julieta
    Nadal, Marga
    Sanjuan, Xavier
    Marin, Fatima
    Vidal, Joana
    Montal, Robert
    Moreno, Victor
    Bellosillo, Beatriz
    Argiles, Guillem
    Elez, Elena
    Dienstmann, Rodrigo
    Montagut, Clara
    Tabernero, Josep
    Capella, Gabriel
    Salazar, Ramon
    MOLECULAR CANCER THERAPEUTICS, 2016, 15 (05) : 1106 - 1112
  • [50] KRAS mutations and sensitivity to anti-EGFR monoclonal antibodies in metastatic colorectal carcinoma: an open issue
    Silvestris, Nicola
    Tommasi, Stefania
    Santini, Daniele
    Russo, Antonio
    Simone, Gianni
    Petriella, Daniela
    Maiello, Evaristo
    Tonini, Giuseppe
    Colucci, Giuseppe
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2009, 9 (05) : 565 - 577
12345